STAT+: Pharmalittle: Compromise reached on Covid-19 vaccine patent waivers; Biogen reports upbeat data on its Alzheimer’s drug

After 18 months of talks, a compromise was reached on a proposal to waive intellectual property rights for Covid-19 medical products.

Hello, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? Perhaps a cup or two of stimulation is in order. As you know, a prescription is not required. Our choice today is pumpkin spice. So feel free to indulge as you attack the laundry list of meetings and deadlines that await. Meanwhile, we have once again assembled a list of tidbits for you to peruse and help you on your way. Hope you have a smashing day and, as always, do drop us a line when you hear something saucy. …

After 18 months of talks, a compromise was reached on a proposal to waive intellectual property rights for Covid-19 medical products, STAT reports, citing this document, which was confirmed by a trade official familiar with the negotiations. For the moment, the agreement reached between the European Union, South Africa, India, and the United States, only covers vaccines, but in six months could be extended to therapies and diagnostics. Nonetheless, patient advocates criticized the delay and also noted the agreement would not grant technology transfers, so that other manufacturers could produce versions of a Covid-19 shot.

Continue to STAT+ to read the full story…